| Immune reconstitution/immunocompetence in recipients of kidney plus hematopoietic stem/facilitating cell transplants JR Leventhal, MJ Elliott, ES Yolcu, LD Bozulic, DJ Tollerud, JM Mathew, ... Transplantation 99 (2), 288-298, 2015 | 144 | 2015 |
| Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study C Cutler, SJ Lee, S Arai, M Rotta, B Zoghi, A Lazaryan, A Ramakrishnan, ... Blood, The Journal of the American Society of Hematology 138 (22), 2278-2289, 2021 | 140 | 2021 |
| Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and … D Buchbinder, DL Kelly, RF Duarte, JJ Auletta, N Bhatt, M Byrne, ... Bone marrow transplantation 53 (5), 535-555, 2018 | 95 | 2018 |
| Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and … Y Inamoto, N Valdés-Sanz, Y Ogawa, M Alves, L Berchicci, J Galvin, ... Bone marrow transplantation 54 (5), 662-673, 2019 | 89 | 2019 |
| Apoptosis induced by granzyme B-glycosaminoglycan complexes: implications for granule-mediated apoptosis in vivo JP Galvin, LHA Spaeny-Dekking, B Wang, P Seth, CE Hack, CJ Froelich The Journal of Immunology 162 (9), 5345-5350, 1999 | 68 | 1999 |
| Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the Late Effects and Quality of Life Working Committee of the Center for … DL Kelly, D Buchbinder, RF Duarte, JJ Auletta, N Bhatt, M Byrne, ... Biology of Blood and Marrow Transplantation 24 (2), 228-241, 2018 | 58 | 2018 |
| Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study V Gupta, HE Kosiorek, A Mead, RB Klisovic, JP Galvin, D Berenzon, ... Biology of Blood and Marrow Transplantation 25 (2), 256-264, 2019 | 54 | 2019 |
| Pre-transplant emotional support is associated with longer survival after allogeneic hematopoietic stem cell transplantation KB Ehrlich, GE Miller, T Scheide, S Baveja, R Weiland, J Galvin, J Mehta, ... Bone marrow transplantation 51 (12), 1594-1598, 2016 | 52 | 2016 |
| Structural racism is a mediator of disparities in acute myeloid leukemia outcomes IE Abraham, GH Rauscher, AA Patel, WB Pearse, P Rajakumar, M Burkart, ... Blood, The Journal of the American Society of Hematology 139 (14), 2212-2226, 2022 | 44 | 2022 |
| Urban children's perceptions of violence K Sheehan, LE Kim, JP Galvin Archives of pediatrics & adolescent medicine 158 (1), 74-77, 2004 | 37 | 2004 |
| Tempering allorecognition to induce transplant tolerance with chemically modified apoptotic donor cells DP McCarthy, J Bryant, JP Galvin, SD Miller, X Luo American Journal of Transplantation 15 (6), 1475-1483, 2015 | 30 | 2015 |
| Aging‐associated dysregulation of homeostatic immune response termination (and not initiation) G Pattabiraman, K Palasiewicz, JP Galvin, DS Ucker Aging Cell 16 (3), 585-593, 2017 | 23 | 2017 |
| Reproductive accommodations for gestation in the atlantic guitarfish, Rhinobatos lentiginosus, Rhinobatidae WC Hamlett, MK Hysell, J Galvin, R Spieler Journal of the Elisha Mitchell Scientific Society, 199-208, 1998 | 21 | 1998 |
| Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: a multicenter chart review SG Holtan, J Yu, HK Choe, D Paranagama, J Tang, A Naim, J Galvin, ... Bone marrow transplantation 57 (10), 1581-1585, 2022 | 17 | 2022 |
| Regulation of the kinase RSK1 by arsenic trioxide and generation of antileukemic responses JP Galvin, JK Altman, A Szilard, DJ Goussetis, E Vakana, A Sassano, ... Cancer biology & therapy 14 (5), 411-416, 2013 | 15 | 2013 |
| Impact of race on outcomes in intermediate-risk acute myeloid leukemia IE Abraham, AA Patel, H Wang, JP Galvin, O Frankfurt, L Liu, I Khan Cancer Causes & Control 32, 705-712, 2021 | 9 | 2021 |
| Eight year follow-up of a phase 2 clinical trial to induce tolerance in living donor renal transplant recipients J Leventhal, J Galvin, J Mathew, L Gallon, D Stare, A Sweeney, J Miller, ... AMERICAN JOURNAL OF TRANSPLANTATION 17, 276-276, 2017 | 9 | 2017 |
| Patient‐reported symptom burden and impact on daily activities in chronic graft‐versus‐host disease J Yu, BK Hamilton, J Turnbull, SK Stewart, A Vernaya, V Bhatt, O Meyers, ... Cancer Medicine 12 (3), 3623-3633, 2023 | 8 | 2023 |
| Seven year follow-up of a phase 2 clinical trial to induce tolerance in living donor renal transplant recipients JR Leventhal, J Galvin, D Stare, L Gallon, J Miller, JM Mathew, ... TRANSPLANTATION 100 (7), S245-S245, 2016 | 7 | 2016 |
| Development of a method for clinical pharmacokinetic testing to allow for targeted Melphalan dosing in multiple myeloma patients undergoing autologous transplant K Sweiss, B Vemu, CC Hofmeister, E Wenzler, GS Calip, JP Galvin, ... British journal of clinical pharmacology 86 (11), 2165-2173, 2020 | 6 | 2020 |
Joseph LeventhalProfessor of Surgery, Northwestern University Feinberg School of MedicineVerified email at nm.org
